The anticipated growth of the monoclonal antibody market in coming years could drive drug developers and manufacturers to increase the speed with which they deliver mAb treatments to patients. One point of concern for companies looking to increase speed to meet demand, is that their equipment might not be up to the task. Inadequate analytical tools are being used that were designed for a specific and limited type of analysis, which cause a significant bottleneck in the therapeutic progress.
The Maurice™ platform is helping to address these concerns by providing fast, reliable analytical tools. Maurice™ offers capillary electrophoresis sodium dodecyl sulfate (CE-SDS) and imaged capillary isoelectric focusing (icIEF) capabilities for analyzing protein size and charge across various stages of biotherapeutic development. The platform has demonstrated the capability to effectively characterize proteins in both cell supernatants and purified samples, delivering high-quality data with sensitivity, reproducibility, and precision.